Multiple myeloma, also known as Kahler's disease, is a type of blood cancer. There's no cure, but treatments can slow its spread and sometimes make symptoms go away. A type of white blood cell called a plasma cell makes antibodies that fight infections in your body. When you have multi...
During ASCO 2023, investigators presented updated findings from the pivotal phase 1/2 MajesTEC-1 study (NCT03145181; NCT04557098) evaluating teclistamab in patients with relapsed/ refractory multiple myeloma who received at least 3 prior lines of treatment. Previous findings from the study led to...
REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM (multiple myeloma) who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients ab...
In many cases, though, the cancer returns (relapses) or begins to grow again during treatment (refracts). When that happens, doctors design a plan for treating relapsed/refractory multiple myeloma (RRMM). There Is No One-Size-Fits-All Treatment Treatment of RRMM must be tailored to each ...
Blood. 2023;142(suppl 1):1028. doi.10.1182/blood-2023-178933 Sidiqi MH, Corradini P, Purtill D, et al. Efficacy and safety in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines who received a single infusion of ciltacabtagene a...
The global multiple myeloma therapeutics market size was valued at USD 20.87 billion in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2030
“The diagnosis, workup, and treatment of myeloma have dramatically changed over the past 10 years. The therapeutic goal is to obtain deep remissions that translate into improved progression-free and overall survival. With combination therapy using immunomodulatory drugs, proteasome inhibitors, monoclonal...
TREATMENT FOR MULTIPLE MYELOMA (MM)The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.LECLAIR, StéphaneENDELL, JanHRTLE, Stefan
A therapeutic agent for multiple myeloma is provided. A therapeutic agent for multiple myeloma comprising a synoviolin activity inhibitor as an active ingredient. Specific examples of synoviolin activity inhibitors include naphthoquinone derivatives having specific substituents, 1,3,5-triazine derivatives ...